Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Dietlein

Showing results (111-120 of 141) with videos related to

Pageof 15
Sort By:
Nuklearmedizin. Nuclear Medicine|February 4, 2010
Development of anti-CD30 radioimmunoconstructs (RICs) for treatment of Hodgkin's lymphoma. Studies with cell lines and animal studiesMarkus Dietlein, S M Börner, T Fischer, et al.
Hematological Oncology|March 21, 2022
Phase II study of fixed-duration single-agent ibrutinib in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: A report from the German Hodgkin Study GroupDennis A Eichenauer, Ina Bühnen, Annette Plütschow, et al.
European Journal of Haematology|August 30, 2023
Prognostic value of baseline metabolic tumor volume (MTV) for forecasting chemotherapy outcome in early-stage unfavorable Hodgkin lymphoma: Data from the phase III HD17 trialLutz van Heek, Jasmin Weindler, Claudia Gorniak, et al.
Plos One|January 12, 2013
Prognostic impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with erlotinibMatthias Scheffler, Thomas Zander, Lucia Nogova, et al.
International Journal of Radiation Oncology, Biology, Physics|April 17, 2024
Involved-site Radiation Therapy is Equally Effective and Less Toxic Than Involved-field Radiation Therapy in Patients Receiving Combined Modality Treatment for Early-stage Unfavorable Hodgkin Lymphoma-An Analysis of the Randomized Phase 3 HD17 Trial of the German Hodgkin Study GroupJohannes Rosenbrock, Helen Kaul, Michael Oertel, et al.
International Journal of Radiation Oncology, Biology, Physics|April 13, 2015
Relapse analysis of irradiated patients within the HD15 trial of the German Hodgkin Study GroupJan Kriz, Gabriele Reinartz, Markus Dietlein, et al.
The Lancet. Oncology|November 15, 2017
Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study GroupDennis A Eichenauer, Annette Plütschow, Stefanie Kreissl, et al.
Blood Advances|June 30, 2026
Validation of the newly introduced Deauville Score 5a in patients treated for advanced-stage classic Hodgkin LymphomaSimon Leiders, Dominic Ufton, Helen Kaul, et al.
Blood|April 19, 2015
A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphomaAchim Rothe, Stephanie Sasse, Max S Topp, et al.
Organic & Biomolecular Chemistry|March 22, 2023
Synthesis and evaluation of radioiodinated estrogens for diagnosis and therapy of male urogenital tumoursFeodor Braun, Marcel Jaschinski, Philipp Täger, et al.
Pageof 15

Showing results (111-120 of 141) with videos related to

Sort By:
Pageof 15
Nuklearmedizin. Nuclear Medicine|February 4, 2010
Development of anti-CD30 radioimmunoconstructs (RICs) for treatment of Hodgkin's lymphoma. Studies with cell lines and animal studiesMarkus Dietlein, S M Börner, T Fischer, et al.
Hematological Oncology|March 21, 2022
Phase II study of fixed-duration single-agent ibrutinib in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: A report from the German Hodgkin Study GroupDennis A Eichenauer, Ina Bühnen, Annette Plütschow, et al.
European Journal of Haematology|August 30, 2023
Prognostic value of baseline metabolic tumor volume (MTV) for forecasting chemotherapy outcome in early-stage unfavorable Hodgkin lymphoma: Data from the phase III HD17 trialLutz van Heek, Jasmin Weindler, Claudia Gorniak, et al.
Plos One|January 12, 2013
Prognostic impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with erlotinibMatthias Scheffler, Thomas Zander, Lucia Nogova, et al.
International Journal of Radiation Oncology, Biology, Physics|April 17, 2024
Involved-site Radiation Therapy is Equally Effective and Less Toxic Than Involved-field Radiation Therapy in Patients Receiving Combined Modality Treatment for Early-stage Unfavorable Hodgkin Lymphoma-An Analysis of the Randomized Phase 3 HD17 Trial of the German Hodgkin Study GroupJohannes Rosenbrock, Helen Kaul, Michael Oertel, et al.
International Journal of Radiation Oncology, Biology, Physics|April 13, 2015
Relapse analysis of irradiated patients within the HD15 trial of the German Hodgkin Study GroupJan Kriz, Gabriele Reinartz, Markus Dietlein, et al.
The Lancet. Oncology|November 15, 2017
Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study GroupDennis A Eichenauer, Annette Plütschow, Stefanie Kreissl, et al.
Blood Advances|June 30, 2026
Validation of the newly introduced Deauville Score 5a in patients treated for advanced-stage classic Hodgkin LymphomaSimon Leiders, Dominic Ufton, Helen Kaul, et al.
Blood|April 19, 2015
A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphomaAchim Rothe, Stephanie Sasse, Max S Topp, et al.
Organic & Biomolecular Chemistry|March 22, 2023
Synthesis and evaluation of radioiodinated estrogens for diagnosis and therapy of male urogenital tumoursFeodor Braun, Marcel Jaschinski, Philipp Täger, et al.
Pageof 15